טוען...
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
FLT3-ITD and FLT3-TKD mutations were observed in approximately 20 and 10% of acute myeloid leukemia (AML) cases, respectively. FLT3 inhibitors such as midostaurin, gilteritinib and quizartinib show excellent response rates in patients with FLT3-mutated AML, but its duration of response may not be su...
שמור ב:
| הוצא לאור ב: | Biomedicines |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7459983/ https://ncbi.nlm.nih.gov/pubmed/32722298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8080245 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|